|
|
Article: Bavarian Nordic and GlaxoSmithKline Enter into Global Collaboration on IMVAMUNE.
- Article from:
- Business Wire
- Article date:
- July 15, 2004
CopyrightCOPYRIGHT 2004 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
COPENHAGEN, Denmark -- Bavarian Nordic A/S and GlaxoSmithKline (GSK) have entered into an international collaboration on the production and marketing of Bavarian Nordic's smallpox vaccine IMVAMUNE(TM), which is based on Bavarian Nordic's proprietary MVA-BN(R) technology.
Under the contract, Bavarian Nordic will transfer its technology on production and use of IMVAMUNE(TM) to GSK. GSK will then manufacture and market the IMVAMUNE(TM) smallpox vaccine to most international markets, including North and South America, Japan as well as a number of important EU-markets, including Great Britain and France.
Bavarian Nordic will continue to manufacture and market ...